Skip to content
TirzepatideReport

Tirzepatide monograph · Evidence review

boostAGErx Tirzepatide Review: Cost, the 28-Day Billing Catch & Honest Verdict (2026)

An honest 2026 review of boostAGErx tirzepatide — a 28-day billing cycle that adds a thirteenth charge a year, and a JavaScript-only pricing page.

Researched & written by Alan Pierce · last updated

Clinical Pharmacology Writer

On this page

Editorial pick

CoreAge Rx

$149/mo flat

Doctor-reviewed tirzepatide with one flat price and built-in human support.

Advertising disclosure · we may earn a commission at no extra cost to you.

Check availability
vs median
$120/mo below the $269 median
Market
$109–$429/mo across 396 providers
Dispensed
Compounded tirzepatide (503A)

Popular alternative

WellMedr

Prices tirzepatide the same at every dose — and never publishes the standing rate that price applies to.

$99/mo advertised "starting at" (discounted; standing rate not published)

Check WellMedr availability

This review that boostAGErx's pricing page renders entirely in JavaScript — the static HTML body is empty, matching a known pattern where nothing about the price is readable without running the site's script bundle. Everything about pricing below is rather than independently reconfirmed this check.

Live verification was limited

This review that boostagerx.com's page loads, but the static HTML contains no readable pricing content — it's rendered entirely client-side in JavaScript. Every pricing claim below is verified August 1, 2026, not re-checked this check. Visit boostagerx.com directly to confirm current terms before committing.

§ boostAGErx — The 28-Day Billing Math

ItemDetail
Advertised rate$145/mo, billed every 28 days
Annual charges13, not 12
True annual cost$1,885 — an effective $157/mo
$95/mo rateRequires a 12-month plan paid upfront
Verified: the pricing page renders entirely in JavaScript, with no static content to independently verify.

What boostAGErx is

BoostAGErx is a longevity-focused telehealth service, selling compounded GLP-1 weight management alongside peptide therapy such as sermorelin. It serves all 50 states, is 100% online with licensed providers, and includes free shipping and a clinical evaluation.

The 28-day billing catch

This is the detail most worth knowing: boostAGErx bills on a 28-day cycle, not a calendar month. That means thirteen charges a year instead of twelve — the advertised $145/month tirzepatide rate works out to $1,885 a year, an effective $157/month. A lower $95/month rate is advertised, but that requires a 12-month plan paid upfront.

The 'membership fee' naming contradiction

BoostAGErx's own terms call the recurring charge a "membership fee", while its marketing carousel states "No Membership Fees Ever" — a direct contradiction worth clarifying before signing up. That membership fee is refunded in full if you're not approved, but shipped compounded medication itself is non-refundable.

The brand-vs-compounded question

BoostAGErx dispenses compounded tirzepatide, not the FDA-approved branded product. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

BoostAGErx's real strengths: free shipping and clinical evaluation, a full refund if not approved, peptide therapy offered alongside GLP-1s, and all-50-state coverage through a fully online model. The trade-offs: the 28-day billing cycle adds a thirteenth annual charge, the $95 rate requires a full year prepaid, "membership fee" language contradicts a "no fees ever" marketing claim, shipped medication is non-refundable, and this review's own attempt to verify any of the pricing live was blocked by client-side rendering. As with any GLP-1 program, calculate the true annual cost — not just the advertised monthly figure — before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-11, and better than semaglutide head-to-head2 — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

BoostAGErx's headline price looks competitive, but the 28-day billing cycle quietly adds a thirteenth annual charge, and this review couldn't verify any of it live since the site renders its pricing entirely in JavaScript. Do the annual-cost math yourself before comparing it to a true monthly rate elsewhere. For a provider with genuinely calendar-month billing this review could verify live, compare bmiMD or CoreAge Rx. Fitish uses a similar 28-day cycle — see that review too before assuming a low headline rate matches a calendar month. See our best tirzepatide providers ranking for the full field.

Frequently asked questions

How much does tirzepatide cost through boostAGErx?

$145/month advertised, but billed every 28 days rather than monthly — that's 13 charges a year, working out to an effective $157/month ($1,885/year).

Why couldn't this review verify boostAGErx's pricing directly?

The site's pricing page renders entirely in JavaScript — the static HTML body contains no readable price content.

Does boostAGErx charge a membership fee?

Its own terms call the recurring charge a "membership fee," which contradicts a "No Membership Fees Ever" claim in its marketing carousel.

References(2)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices · This page last updated August 2026

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Related monograph sections

View all sections